Key result
Prophylactic atropine cuts contrast-induced ventricular pauses ~88% vs placebo during coronary angiography.
Why the study?
Contrast-induced bradycardia during coronary angiography is common and unpredictable, and effective prevention strategies were needed.
RCT (n=90)
Double-blind
Answers are grounded in this paper and cite their sources.
May warrant prophylactic atropine during coronary angiography; confirms efficacy in this RCT.
A double-blind study of 90 patients undergoing coronary angiography was performed to determine the safety and efficacy of 0.6 mg atropine sulfate in preventing contrast-induced bradycardia. Coronary angiography performed using the Sones technique resulted in ventricular pauses of greater than 2 seconds in 3 of 49 patients (6%) who received prophylactic atropine and 20 of 41 patients (49%) receiving placebo. Though the pauses were usually due to atrial asystole, 26% of those with greater than 2 second pauses did so because of transient complete heart block. Prophylactic atropine did increase resting heart rate but did not cause other arrhythmias or increase the frequency of angina pectoris despite the presence of severe coronary disease. Our data indicate that contrast-induced asystole is very common, cannot be predicted by consideration of "precatheterization data," and can be prevented effectively and safely by use of prophylactic atropine sulfate.
No takes yet. Share an insight, caveat, or question.
Richards et al. (1981) conducted an RCT in Contrast-induced bradycardia (n=90). Atropine sulfate vs. Placebo was evaluated on Ventricular pauses of greater than 2 seconds. Prophylactic administration of atropine sulfate reduced the incidence of contrast-induced ventricular pauses greater than 2 seconds to 6% compared to 49% with placebo during coronary angiography.
Synapse has enriched 10 related papers. Consider them for comparative context: